Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2018
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose EvaluationStephanie N Taylor, David H Morris, Ann K Avery, et al.Pediatrics|January 19, 2008
Adolescent immunizations and other clinical preventive services: a needle and a hook?Karen R Broder, Amanda C Cohn, Benjamin Schwartz, et al.Lancet (London, England)|April 17, 2025
Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre studyJonathan D C Ross, Janet Wilson, Kimberly A Workowski, et al.Emerging Infectious Diseases|May 22, 2012
Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010Robert D Kirkcaldy, Peter Augostini, Lenore E Asbel, et al.Journal of Virology|December 22, 2006
Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expressionHenry Radziewicz, Chris C Ibegbu, Marina L Fernandez, et al.Microbiology Spectrum|August 20, 2024
Molecular investigation of <i>Treponema pallidum</i> strains associated with ocular syphilis in the United States, 2016-2020Allan Pillay, Kendra Vilfort, Alyssa Debra, et al.Plos One|January 14, 2020
Successful isolation of Treponema pallidum strains from patients' cryopreserved ulcer exudate using the rabbit modelLara E Pereira, Samantha S Katz, Yongcheng Sun, et al.AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.JAMA Internal Medicine|January 8, 2024
Early Tecovirimat Treatment for Mpox Disease Among People With HIVBruce Aldred, Robert H Lyles, Jane Y Scott, et al.Annals of Internal Medicine|December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized StudyAmy E Colson, Gordon E Crofoot, Peter J Ruane, et al.Pageof 9